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Most human tumors have abnormal numbers of chromosomes, a condition known as aneuploidy. The mitotic 
checkpoint is an important mechanism that prevents aneuploidy by restraining the activity of the anaphase-
promoting complex (APC). The deubiquitinase USP44 was identified as a key regulator of APC activation; 
however, the physiological importance of USP44 and its impact on cancer biology are unknown. To clarify the 
role of USP44 in mitosis, we engineered a mouse lacking Usp44. We found that USP44 regulated the mitotic 
checkpoint and prevented chromosome lagging. Mice lacking Usp44 were prone to the development of spon-
taneous tumors, particularly in the lungs. Additionally, USP44 was frequently downregulated in human lung 
cancer, and low expression correlated with a poor prognosis. USP44 inhibited chromosome segregation errors 
independent of its role in the mitotic checkpoint by regulating centrosome separation, positioning, and mitot-
ic spindle geometry. These functions required direct binding to the centriole protein centrin. Our data reveal 
a new role for the ubiquitin system in mitotic spindle regulation and underscore the importance of USP44 in 
the pathogenesis of human cancer.
Introduction
While aneuploidy has been observed in human tumors for more 
than a century, its role in the genesis of cancer continues to be 
a point of debate. Recent mouse data suggest that aneuploidy 
itself is capable of driving the development of tumors (1–3); how-
ever, only some mouse models that are prone to aneuploidy have 
increased tumor susceptibility (4). This suggests that there may 
be a select group of chromosome instability (CIN) genes that 
play a disproportionally important tumor-suppressive role that is 
not necessarily related to the magnitude of aneuploidy produced 
in mutant animals. To date, only a handful of such genes have 
been identified, many with limited evidence for direct impor-
tance for human tumors. To prevent errors in mitosis, a complex 
machinery known as the spindle assembly checkpoint, or mitotic 
checkpoint, acts to delay the onset of anaphase until all sister 
chromatids are properly attached to spindle microtubules (5, 6). 
Unoccupied kinetochores lead to the formation of an inhibitory 
complex, comprising MAD2, BUBR1, and BUB3, known as the 
mitotic checkpoint complex (MCC) (7). This complex inhibits the 
activity of the large, multi-subunit ubiquitin E3 ligase known as 
the anaphase-promoting complex (APC) through binding to the 
co-activating subunit CDC20 (APCCDC20) (8, 9). When all kineto-
chores are properly attached to spindle microtubules, the check-
point becomes silenced and the MCC dissociates from APCCDC20, 
leading to UBCH10 (UBE2C)–dependent polyubiquitination 
and proteasomal degradation of cyclin B1 (CCNB1) and securin 
(PTTG1) — two proteins that inhibit the activity of the enzyme 
separase (ESPL1) (10, 11). Once liberated from this inhibition, 
separase cleaves the ring-like cohesin structures that connect rep-
licated sister chromatids, leading to the onset of anaphase (12).
Two recent functional genetic screens identified the deubiquiti-
nase USP44 as an important regulator of the mitotic checkpoint 
(13, 14). Depletion of USP44 leads to unscheduled silencing of 
the mitotic checkpoint, increasing the risk of entry into anaphase 
prior to the complete attachment of all chromosomes to the 
mitotic spindle. A model was proposed in which the checkpoint 
was silenced through a mechanism involving UbcH10-dependent 
polyubiquitination of CDC20 that leads to the dissociation of the 
MCC (14, 15). USP44 is thought to counteract this process by deu-
biquitinating CDC20, thereby maintaining the complex between 
the MCC and CDC20 (16).
To address the physiological relevance of USP44 and to clarify 
its role in mitosis, we engineered a mouse with a deletion of the 
Usp44 gene. In contrast to most other mitotic regulators, USP44 
is not essential for cell viability or mouse embryogenesis, as 
Usp44-homozygous-null mice were born at Mendelian frequen-
cies and were overtly healthy. Cells from Usp44-null animals 
have cellular and biochemical features consistent with a role for 
USP44 in regulating the mitotic checkpoint. Surprisingly, how-
ever, correction of the checkpoint defect through pharmacologic 
inhibition of APC/C failed to correct chromosome mis-segrega-
tion. We describe a novel interaction that is required in order 
to prevent chromosome lagging between USP44 and the centri-
ole protein centrin. We observe that a pool of USP44 localizes 
to the centrosome and that cells lacking USP44 have abnormal 
spindle geometry due to abnormal centrosome separation and 
positioning. At the physiological level, mice lacking USP44 are 
highly prone to spontaneous tumors, particularly in the lungs. 
We also found significant reductions in USP44 expression in 
human bronchial adenocarcinomas, and strikingly, these reduc-
tions strongly predicted a poor prognosis. These data establish 
a novel role for USP44 in centrosome functioning and mitotic 
spindle formation and identify USP44 as a key tumor suppressor.
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Results
Usp44 loss causes chromosome mis-segregation and aneuploidy. To study 
the role of USP44 in mice, we inserted LoxP sites flanking exon 1 
such that, in the presence of Cre recombinase, it would be excised 
in its entirety (Figure 1A). This exon encodes approximately 75% 
of the residues of USP44 (aa 1–475 based on NM_001206851.1), 
including the N-terminal zinc finger domain and the catalytic 
cysteine. To generate the null allele (Usp44–), we crossed Usp44+/h 
mice with the protamine-Cre (Prm-Cre) strain to excise exon 1 in 
the male germline (17). To generate homozygous-null animals, 
we intercrossed Usp44+/– mice. Surprisingly, Usp44–/– animals were 
viable, were obtained at near-Mendelian frequencies, and had no 
substantial changes in growth patterns compared with Usp44+/– 
or wild-type mice (Supplemental Figure 1, A and B; supple-
mental material available online with this article; doi:10.1172/
JCI63084DS1). Usp44-null animals were able to interbreed and 
produce normal litter sizes. Despite extensive efforts (see Meth-
ods), we were unable to identify an antibody that can detect 
endogenous USP44 by immunoblotting. The deletion of exon 1 
was therefore verified by Southern blotting in ES cells, as well as 
RT-PCR and direct sequencing in MEFs (Supplemental Figure 1, 
C–F). On this basis, we conclude that USP44 is not essential for 
mouse development.
To understand the role of USP44 in mitotic progression, we 
followed Usp44-null and wild-type MEFs through unperturbed 
mitoses by live-cell fluorescence microscopy. Chromosomes were 
visualized through the expression of a fusion between histone 
H2B and yellow fluorescent protein (H2B-YFP) (18). We found 
Figure 1
USP44 loss leads to chromosome mis-segregation. (A) Strategy for targeting the Usp44 gene in mice. The Usp44 gene with indicated EcoRV 
sites, location of the Southern probe, the targeting vector with NeoR, Frt and loxP sites, and the resulting hypomorphic floxed and null alleles. (B) 
MEFs of the indicated genotypes were transduced with H2B-YFP to visualize chromosomes and followed through mitosis by live-cell microscopy. 
Values represent the mean ± SEM of 3 independent lines per genotype (n = 137 Usp44+/+ and n = 91 Usp44–/–). (C) Still image of lagging chro-
mosome captured from live-cell time-lapse microscopy from Usp44–/– MEFs transduced with H2B-YFP. Scale bar: 5 μm. (D) Cells encountering 
a lagging chromosome were scored for the number of chromosomes involved in the error. Graph represents the percent incidence of each error 
in the overall population of cells observed. *P < 0.05, 2-tailed unpaired t test.
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a significant increase in chromosome segregation errors in the 
absence of USP44 compared with controls, with the vast majority 
involving chromosome lagging (Figure 1, B and C). The majority 
of cells with errors had 1–3 lagging chromosomes (Figure 1D). 
We next examined whether this chromosome mis-segregation 
resulted in aneuploidy by performing metaphase chromosome 
counts on Giemsa-stained metaphases following short-term cul-
ture in colcemid. We found a significant increase in aneuploidy in 
passage 5 Usp44–/– MEFs compared with controls (Figure 2A). We 
observed no chromosome breaks or gaps in the Giemsa-stained 
chromosomes, nor by spectral karyotyping (SKY), indicating that 
the defect involves the loss or gain of whole chromosomes (Fig-
ure 2, C and D). Aneuploidy was also seen in splenocytes in vivo, 
with rates that increased with age (Figure 2, A and B). To investi-
gate whether these mitotic defects might result from a dominant 
negative function of residual truncated USP44 protein resulting 
from the use of an alternative start site, we cloned a cDNA cor-
responding to a potential ORF using the next in-frame methio-
nine in exon 2 as the new start site (Supplemental Figure 2A). This 
construct (USP44C25HA) encodes an approximately 
25-kDa protein representing the C terminus of USP44. 
To examine its potential impact on mitosis, we cloned 
it into the lentiviral vector TSiN and transduced wild-
type MEFs. In repeated experiments, we noted that the 
fragment was not efficiently expressed compared with 
full-length USP44 (Supplemental Figure 2B), indicat-
ing a potential inherent instability of this fragment 
of USP44. Additionally, cells expressing USP44C25HA 
exhibited no increase in mitotic errors compared with 
control MEFs (Supplemental Figure 2C). In contrast, 
we previously observed that overexpression of full-
length USP44 results in an increase in mitotic errors in 
MEFs (19). These data strongly suggest that any resid-
ual USP44 fragment is likely present in small amounts 
and has no dominant negative effect on mitosis. Taken 
together, these data suggest that USP44 is required in 
order to prevent chromosome mis-segregation and 
that the loss of this function results in aneuploidy.
USP44 has a checkpoint-independent role in regulat-
ing chromosome segregation. To examine the impact of 
USP44 loss on checkpoint functioning, we studied 
the ability of Usp44-null MEFs to initiate and main-
tain checkpoint-dependent mitotic arrest. After the 
addition of nocodazole, H2B-YFP–expressing MEFs 
were marked in early prophase and followed by use 
of time-lapse microscopy. We observed a significant decrease in 
the duration of mitotic arrest in Usp44-null MEFs compared with 
controls, consistent with a reinforcing role in the mitotic check-
point (Figure 3A). In the normal progression through mitosis, cells 
rarely would need to maintain a checkpoint arrest lasting hours. 
Certain defects in the mitotic checkpoint (e.g., Bub1b [BUBR1] or 
Mad2l1 [MAD2] loss), however, have a direct effect on the timing 
of mitosis through the premature activation of APC (20). We fol-
lowed H2B-YFP–expressing MEFs through unchallenged mitoses 
and measured the time required to progress from prophase to 
anaphase. We observed a significant mitotic acceleration in MEFs 
lacking USP44 compared with wild-type MEFs (Figure 3B). This 
prompted us to examine the amount of MAD2 bound to CDC20 
in mitotic MEFs. Consistent with prior reports, we found an 
average reduction of 57% in the recovery of MAD2 from CDC20 
immunoprecipitates in Usp44-null cells compared with controls 
(Supplemental Figure 3, A and B). There were no changes in the 
overall levels of the APC substrates cyclin B1 or securin or of the 
APC components CDC20, CDC27, or BUBR1 in immunoblots 
Figure 2
USP44 loss leads to whole-chromosome aneuploidy in 
vitro and in vivo. (A) Chromosome counts were performed 
on MEFs and splenocytes of the indicated genotype at 
the indicated ages. Values represent the mean ± SEM of 
3 independent lines or animals. n = 150 for each genotype. 
(B) Incidence of splenocytes from A with the indicated 
numbers of chromosomes at 15 months. The graph rep-
resents the percent incidence of cells with each chromo-
some count out of the entire cohort of cells observed. (C) 
Representative spectral karyotype (SKY) from Usp44–/– 
MEFs showing pseudo-diploidy. Note that despite the nor-
mal chromosome number (i.e., 40), there is trisomy 15 
and monosomy 19. (D) Complete SKY data from C. n = 20. 
*P < 0.05, 2-tailed unpaired t test.
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(Supplemental Figure 4, A and B). We did observe an increase 
in the levels of MAD2, and we hypothesized that this may have 
been a cellular response in an attempt to compensate for USP44 
loss. Examination of Usp44–/–Mad2l1+/– MEFs suggested that this 
was not the case, however, as USP44 loss did not exacerbate the 
chromosome instability phenotype resulting from reduced MAD2 
(Supplemental Figure 4, C–E). We further found no evidence of 
cyclin B1 destabilization in fixed or living cells by microscopy 
(Supplemental Figure 5, A and B). This may reflect the modest 
(~50%) reduction in MAD2 association with CDC20, as degrada-
tion of cyclin B is not overtly accelerated in MAD2L1+/– human or 
mouse cells despite clear mitotic defects (21).
We next sought to establish whether the mitotic defects would 
be corrected by providing Usp44-null MEFs with additional time to 
achieve proper microtubule-kinetochore attachments. To accom-
plish this, we used a recently described small molecule inhibitor 
of APC (proTAME, ref. 22). At high doses, this inhibitor leads to 
complete metaphase arrest, consistent with inhibition of APC. 
We incubated cells with a low dose (6 μM) of proTAME, such that 
anaphase was delayed by 12–18 minutes without inducing mitotic 
errors (Figure 3, C and D). Consistent with a prior report, this 
strategy was able to correct the mitotic defects seen in Mad2l1+/– 
MEFs down to levels seen in wild-type MEFs (compare with Fig-
ure 1B), validating the approach (Figure 3E; ref. 22). Surprisingly, 
despite a delay in anaphase onset, APC inhibition was unable to 
prevent chromosome mis-segregation in Usp44-null cells. We con-
clude that while there is a clear yet modest defect in mitotic check-
point activity in the absence of USP44, this does not seem to be 
the primary mechanism behind the chromosome instability seen 
in cells or tissues lacking this enzyme.
A novel USP44-centrin complex is required in order to prevent chro-
mosome mis-segregation. Lagging chromosomes result from aber-
rant attachments of spindle microtubules to kinetochores, most 
commonly those resulting from a single kinetochore attached 
to both spindle poles — an error known as a merotelic attach-
ment. Increased levels of lagging chromosomes may therefore 
result from either defects in the correction of these errors, which 
depends on the Aurora B “error correction pathway,” or an 
increased rate of formation of erroneous attachments (23–25). We 
found no defects in the level, localization, or activity of Aurora B 
Figure 3
Correction of the checkpoint defect in Usp44-null cells does not prevent mitotic errors. (A) MEFs of the indicated genotype were transduced 
with H2B-YFP, followed by live-cell microscopy. Mitotic arrest duration was determined by calculating the time from nuclear envelope breakdown 
(NEBD) to chromosome decondensation. Graph represents the mean percentage ± SEM of cells remaining in mitosis at each time point (3 lines 
per genotype). Total n = 50–90 cells for each genotype per condition. (B) The interval between NEBD and anaphase was determined in the 
absence of nocodazole for MEFs of the indicated genotypes. The graph represents the cumulative incidence of anaphase at each time point 
(mean ± SEM of 3 lines). Total n = 50–60 cells for each genotype. (C) Experimental scheme for D and E. MEFs expressing H2B-YFP were marked 
in prophase and followed by time-lapse microscopy to determine mitotic duration and chromosome mis-segregation. Two hours after the addi-
tion of proTAME, new prophase cells were selected and similarly examined. (D) Duration of mitosis for Usp44+/+, Usp44–/–, and Mad2l1+/– MEFs 
imaged before and after proTAME addition. The graph represents the mean ± SEM for 3 lines per genotype. Total n = 25–35 cells per time period. 
(E) The effect of proTAME on chromosome mis-segregation in Usp44+/+ (n = 67 before, 83 after), Usp44–/– (n = 65 cells per time period from 3 
MEF lines), and Mad2l1+/– MEFs (n = 20–25 cells per time period, 1 MEF line). The patterned area indicates the proportion of cells encountering 
at least one lagging chromosome. The graph represents the mean ± SEM. *P < 0.05, 2-way ANOVA.
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Figure 4
USP44 is required for proper centrosome separation and spindle geometry. (A) Confocal immunofluorescence microscopy was performed on MEFs 
of the indicated genotypes using antibodies against the indicated proteins. Scale bar:5 μm. (B) Incidence of spindle abnormalities in MEFs of the 
indicated genotypes. Graph represents the mean ± SEM for 3 lines per genotype, with at least n = 20 cells per line. (C) Comparison of the inter-pole 
distance, as defined as the distance between γ-tubulin–positive centrosomes, in metaphases with normal versus abnormal spindle geometry. Images 
collected by confocal immunofluorescence microscopy. Graph represents the mean ± SEM for n = 12–13 metaphases per group regardless of geno-
type. (D) MEFs were transduced with γ-tubulin–CFP and H2B-RFP and followed through unperturbed mitoses with live-cell microscopy. The inter-pole 
distance was calculated at nuclear envelope breakdown (NEBD) and the onset of anaphase in Usp44+/+ (n = 31) and Usp44–/– cells (n = 26), and the 
data are expressed as the ratio between these values. Graph represents the mean ± SEM for cells with normal (n = 45) versus abnormal (n = 14) 
chromosome segregation, regardless of genotype. (E) The incidence of incomplete centrosome separation (inter-pole distance at NEBD <75% that 
at anaphase onset) was determined in MEFs of the indicated genotype from B. The graph represents the percent incidence of cells with incomplete 
centrosome separation in the entire cohort of cells observed. (F and G) Examples of MEFs with normal or abnormal centrosome separation (F) or 
spindle geometry (G) as seen by live-cell microscopy. Scale bars: 5 μm. *P < 0.05, 2-tailed unpaired t test.
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(AURKB) toward the substrate CENP-A in Usp44-null MEFs (Sup-
plemental Figure 6, A and B). We therefore suspected that there 
was an increased rate of formation of merotelic attachments. 
Recent work revealed a connection between spindle defects and 
merotelic attachments (26, 27), leading us to examine the integ-
rity of the centrosome and mitotic spindle. We found a significant 
number of Usp44–/– MEFs with abnormal spindle geometry, with 
the spindle poles not lying perpendicular to the metaphase plate 
(Figure 4, A and B). This corresponded to abnormal placement of 
centrosomes away from the perpendicular axis in these cells. The 
abnormal spindles were characterized as having an acute angle 
between the spindle and the metaphase plate, with nearly 30% of 
Usp44-null cells having an angle of less than 82° compared with 
6% in wild-type MEFs (Supplemental Figure 7, A and B). The cells 
with abnormal spindle geometry also had a significant reduction 
in the inter-pole distance (Figure 4C).
Recently, lagging chromosomes were found to occur at an 
increased frequency in cells experiencing delayed centrosome 
separation (28). Therefore, to further investigate the relation-
ship between the spindle anomalies and chromosome mis-seg-
regation, we performed live-cell microscopy on MEFs express-
ing fluorescent γ-tubulin (TUBG1), in addition to fluorescent 
histone H2B, to allow monitoring of centrosome and DNA 
movements. In cells that successfully completed mitosis, cen-
trosomes largely separated prior to nuclear envelope breakdown 
(NEBD), achieving an inter-centrosome distance of nearly 100% 
of the distance seen at anaphase onset (Figure 4D). In contrast, 
cells that experience a defect in anaphase chromosome move-
ments (mostly lagging chromosomes) had a significant reduc-
tion in the degree of prior centrosome separation, achieving 
on average only 80% of the inter-pole distance determined at 
anaphase onset (Figure 4D). To help explain the increased chro-
Figure 5
USP44 is required for timely centrosome separation. (A and B) MEFs transduced with the indicated USP44 constructs were subjected to 
immunoprecipitation using the indicated antibodies. Precipitates were immunoblotted using antibodies against the indicated proteins. Asterisk 
indicates IgG light chain. (C) N-terminally 6xHis-tagged USP44, GST, or GST–centrin 2 was expressed in bacteria, and resulting extracts were 
mixed, followed by affinity purification with glutathione agarose. Precipitates were immunublotted using the indicated antibodies. (D and E) Confo-
cal immunofluorescence microscopy was performed on methanol-fixed MEFs transduced with USP44Cherry using antibodies against the indicated 
proteins. Scale bar: 5 μm; insets, 1 μm. (F) The level of centrin 2/3 was determined in asynchronous MEFs of the indicated genotypes. Extracts 
were immunoblotted using antibodies for the indicated proteins. (G) Example of an Usp44-null cell with a supernumerary centrin signal at one 
spindle pole. Scale bar: 5 μm. (H) Incidence of one or more extra centrin signals in at least one spindle pole in MEFs of the indicated genotypes. 
Graph represents the mean ± SEM from 3 lines per genotype, 20 cells per line. *P < 0.05, unpaired t test.
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mosome mis-segregation rate seen in the absence of USP44, we 
next evaluated the incidence of incomplete centrosome separa-
tion (defined as <75% separation at NEBD) between wild-type 
and Usp44-null MEFs. There was a substantial and significant 
increase in the rate of incomplete centrosome separation in 
Usp44–/– compared with wild-type MEFs (Figure 4, E and F). To 
examine the connection between abnormal spindle morphology 
and mitotic errors, we monitored cells expressing α-tubulin–
RFP (TUBA1A) and H2B-GFP. We observed that an average of 
26% of Usp44-null cells developed an abnormal spindle, com-
pared with 15% in wild-type controls. However, most cells that 
developed abnormal spindles in the early phases of mitosis even-
tually achieved a metaphase plate that appeared largely normal 
— with the spindle-poles perpendicular to the DNA (Figure 
4G). This suggests that the abnormal spindle geometry seen in 
experiments using fixed cells represent intermediate forms that 
are resolved prior to anaphase. Compiling the data from 118 
cells from 6 cell lines of either genotype, there was a very strong 
association between abnormal spindle morphology and eventu-
al anaphase chromosome movement errors, with 88% of those 
with abnormal spindles going on to experience an error (Fig-
ure 4G and Supplemental Figure 7C). Conversely, 87% of those 
cells that experienced an error had an abnormal spindle shape 
prior to the error. Taken together, these data demonstrate that 
USP44 is required for proper centrosome separation and spindle 
geometry. Defects in these processes that result from USP44 loss 
highly predispose cells to mitotic chromosome mis-segregation 
and cause mitotic errors and aneuploidy.
Figure 6
The USP44-centrin complex is required in order to prevent chromosome mis-segregation. (A and B) MEFs transduced with HA-tagged wild-type 
USP44 (WT), USP44W162A (W162A), USP44W308A (W308A), or empty vector (EV) were subjected to immunoprecipitation using the indicated 
antibodies. Precipitates were immunoblotted using antibodies against the indicated proteins. (C) Confocal immunofluorescence microscopy was 
performed on methanol-fixed MEFs transduced with USP44WTCherry or USP44W162ACherry using antibodies against the indicated proteins. Scale 
bar: 5 μm; insets, 1 μm. (D) Quantitation of USP44Cherry and USP44W162ACherry at centrosomes. Images were captured with identical settings, 
and the cherry signal was normalized to that of γ-tubulin. n = 11 cells from each genotype. Graph represents the mean ± SEM. (E) MEFs of the 
indicated genotype were transduced with empty vector or the indicated USP44 constructs followed by live-cell microscopy. Chromosomes were 
visualized through the expression of H2B-YFP. The graph represents the mean ± SEM of 3 lines per genotype. n = 71–137 total cells per condition. 
(F) Cells treated as in E were fixed and stained with α- and γ-tubulin, followed by confocal microscopy. Spindles with poles off axis were scored 
as abnormal. The graph represents the mean ± SEM of 3 lines per genotype. *P < 0.05, 2-tailed unpaired t test.
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Recently, a large deubiquitinating enzyme (DUB) proteomics 
database was generated (http://falcon.hms.harvard.edu/ipmsms-
dbs/comppass.html) that lists the centriole protein centrin 2 
(CETN2) as a candidate interacting protein of human USP44. We 
therefore tested the ability of endogenous centrin to interact with 
USP44 by co-immunoprecipitation. We observed that centrin 2 is 
specifically recovered with either wild-type USP44 (USP44WTHA) or 
catalytic mutant USP44 (USP44C281AHA; Figure 5A). These results 
were verified by the finding that USP44WTHA was recovered specifi-
cally in centrin 2/3 immunoprecipitates (Figure 5B). The binding 
of USP44 with centrin was also confirmed by GST pull-down from 
bacterially expressed 6xHIS-USP44 and GST–centrin 2, demon-
strating that the interaction is direct (Figure 5C). We next examined 
whether USP44 colocalizes with centrosomes in cells expressing a 
fusion between USP44 and the fluorescent protein mCherry (USP-
44Cherry). In methanol-fixed MEFs, there was obvious colocalization 
of USP44Cherry with the centrosome marker γ-tubulin and centrin 
(Figure 5E and Supplemental Figure 7D). The colocalization was 
most prominent in interphase cells, with little USP44 seen at the 
centrosome in mitotic cells (data not shown), consistent with our 
prior observation that levels of exogenous USP44 are very low in 
mitosis (19). Although we found no change in the level of centrin 
2 in immunoblots (Figure 5F), Usp44-null MEFs had a significant 
increase in cells with 3 centrioles at one pole (Figure 5, G and H). 
We also noted some highly disordered centriole configurations in 
cells overexpressing USP44Cherry, perhaps contributing to the chro-
mosome mis-segregation seen in these cells (Supplemental Figure 
7D and ref. 19). We conclude that USP44 forms a complex with 
centrin 2/3 and localizes to centrosomes.
A conserved centrin-binding domain (CBD) has been defined 
in the centrin partners XPC and SFI1 (Supplemental Figure 8, 
A and B, and refs. 29–31). We scanned the sequence of USP44 
and found two putative CBDs that are highly conserved in 
mammals (Supplemental Figure 8A). To confirm the centrin-
binding capacity of these motifs, we prepared USP44 mutants 
(USP44W162AHA and USP44W308AHA) and examined their abil-
ity to co-precipitate with centrin. We found a profound reduc-
tion in centrin binding to USP44W162AHA, whereas there was 
only a slight reduction in binding to USP44W308AHA (Figure 6, 
A and B). We also observed a dramatic reduction in the local-
ization of USP44W162ACherry to the centrosome, consistent 
with an important role for centrin binding in this localization 
(Figure 6, C and D). We next tested the ability of these mutant 
constructs to correct lagging chromosomes seen in Usp44-
null MEFs. In contrast to the rescue observed with USP44WT, 
transduction with empty virus, USP44C281A, or USP44W162A was 
unable to affect the rate of lagging chromosomes despite equal 
levels of expression (Figure 6E and Supplemental Figure 2B). 
Similarly, complementation of Usp44-null MEFs with USP-
44WTHA restored spindle geometry, whereas USP44C281AHA 
or USP44W162AHA could not (Figure 6F). USP44W162A retained 
catalytic activity toward di-Ub chains in vitro, making catalytic 
inactivity an unlikely cause of its failure to rescue chromosome 
lagging (Supplemental Figure 9, A and B). Taken together, these 
data demonstrate that USP44 forms a complex with centrin 
through a highly conserved motif and that both DUB activity 
and the ability to form a complex with centrin are required in 
order to prevent chromosome lagging.
Figure 7
USP44 is a tumor suppressor. A. Mice 
of the indicated genotypes (n = 27, 27, 
and 25 for Usp44+/+, Usp44+/–, and 
Usp44–/–, respectively), were sacrificed 
at 15 months of age and were dissected 
and scored for visible tumors. Graph rep-
resents the percent incidence of sponta-
neous tumors in the overall cohorts. The 
P value was calculated using Fisher’s 
exact test. (B) Tumor spectrum seen in 
mice from A. All tumor classifications 
were confirmed by histopathology. The 
graph represents the percent incidence 
of each tumor type in the overall cohorts. 
(C) Graph represents the total number of 
tumors per mouse, regardless of histol-
ogy (mean ± SEM) including all that had 
at least 1 tumor. The P value was cal-
culated using a 2-tailed 1-sample t test. 
(D and E) Gross (scale bars: 1 mm) and 
microscopic (scale bars: 50 μm) appear-
ance of representative lung adenoma 
(D) and liver hepatoma (E) from Usp44-
null mice.
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USP44 suppresses tumorigenesis. We generated cohorts of Usp44+/+, 
Usp44+/–, and Usp44–/– mice and aged them for 15 months to deter-
mine the incidence of spontaneous tumors. There was a dramatic 
increase in tumorigenesis in the Usp44-null group, with 12 of 24 
(50%) having at least one tumor type (Figure 7A), and a significant 
increase in tumor burden in Usp44-null animals, with some hav-
ing 2–4 tumors (Figure 7, B and C). The tumor spectrum observed 
was diverse, with 4 distinct histologic types observed (Figure 7, B, 
D, and E). Strikingly, there was a 9-fold increase in the number 
of lung tumors in Usp44-null animals, with histology consistent 
with bronchiolar adenomas. While aneuploidy was not observed in 
the normal tissues, 5 of the 10 lung tumors from Usp44-null mice 
had substantial losses or gains at either chromosome 4 or 7 by 
fluorescence in situ hybridization on paraffin-embedded sections 
(Supplemental Figure 10A). We conclude that Usp44 is a tumor 
suppressor gene that, when deleted, leads to tumorigenesis in the 
context of increased aneuploidy.
Given the striking incidence of lung adenomas in Usp44-null 
animals, we next asked whether there was an association between 
USP44 downregulation and human adenocarcinoma. To accom-
plish this, we queried a microarray expression dataset from 
patient specimens included in the Mayo Clinic Lung Specimen 
Registry. Expression data were obtained from 194 fresh-frozen 
resected lung specimens consisting of tumor and adjacent nor-
mal lung tissues derived from 155 patients with stages I–III lung 
adenocarcinoma. There was a statistically significant reduction 
in the expression of USP44 in all stages of disease compared with 
normal lung as assessed by analyzing 100 normal and 94 tumor 
tissues of mixed stage and outcome (Figure 8A; P < 0.0001). 
To assess the potential clinical significance of USP44 in these 
tumors, we analyzed survival in this patient cohort. As there is 
a significant association of stage and outcome, we limited the 
analysis to the group of patients with stage I disease (n = 69). 
When dividing patients into USP44-low (<27th percentile) versus 
normal (28–100th percentile), we found that low levels of USP44 
had a highly significant negative impact on overall survival 
(P = 0.0014; Figure 8B). To test the frequency of aneuploidy in 
lung adenocarcinoma, we performed FISH for chromosomes 7 
and 8 on archived paraffin sections in a selection of cases with 
normal or low levels of USP44 mRNA using FISH. Compared 
with the results from adjacent normal lung tissues, nearly all 
tumor samples had substantial aneuploidy, with the majority 
exhibiting chromosome gains with up to 10 copies of the ana-
lyzed chromosomes (Supplemental Figure 10B). These results 
demonstrate that aneuploidy is very common in human adeno-
carcinoma of the lung, but suggest that reduced USP44 expres-
sion may be only one of the ways through which this genetic 
instability is achieved. Taken together, our results indicate that 
reduced expression of USP44 is common in patients with lung 
adenocarcinoma and that its reduction is associated with a more 
aggressive tumor biology and poor clinical outcome.
Discussion
The deubiquitinase USP44 was previously identified in two func-
tional genomic screens designed to uncover novel regulators of the 
mitotic checkpoint. Several key questions remained unanswered, 
however, including the physiologic relevance of USP44, whether 
its loss leads to in vivo chromosome instability, whether the 
enzyme has other functions in mitosis, and whether these func-
tions provide antitumor protection in vivo. Using a mouse genetic 
approach, we here provide direct evidence that Usp44 is a tumor 
suppressor in mice and humans, with a particularly important role 
in lung cancer. We confirm the role of USP44 in modulating the 
mitotic checkpoint, though surprisingly, this function appears not 
to be its most essential function. Rather, we found an important 
role for USP44 deubiquitinase activity in regulating centrosome 
positioning and spindle geometry through a direct interaction 
with the centriole protein centrin. This is a previously undescribed 
function involving the ubiquitin-proteasome system that, when 
disrupted, leads to chromosome mis-segregation, aneuploidy, and 
tumorigenesis in vivo.
USP44 and the mitotic checkpoint. We observe that USP44 is required 
for efficient mitotic checkpoint signaling, consistent with the 
reports of others using RNAi. The fact that cells maintain arrest for 
some time in the presence of nocodazole suggests that initiation of 
checkpoint activity is intact, but that this signal is prone to early 
decay. The effect is modest, however, suggesting that APC restraint 
is not entirely lost in the absence of USP44. An effect of similar 
magnitude was observed in cells overexpressing the E2 conjugat-
ing enzyme UBCH10, which is proposed to ubiquitinate CDC20 
(32). These two results are consistent with an antagonistic role 
between the two enzymes as proposed by the Elledge group (14). 
Despite the clear evidence of accelerated anaphase in cells lacking 
USP44, we found no evidence of accelerated degradation of cyclin 
B1. This is not surprising in light of the modest (~50%) reduction 
in MAD2 association with CDC20, as degradation of cyclin B is 
not overtly accelerated in MAD2L1+/– human or mouse cells despite 
the presence of clear mitotic defects (21). Finally, there also may be 
redundancy in the system, with other DUBs taking over the essen-
tial checkpoint-related functions of USP44 upon its loss.
Figure 8
Reduced expression of USP44 is a marker of poor prognosis 
in human adenocarcinoma at the lung. (A) Level of USP44 
mRNA (log2) measured by microarray in lung adenocarcino-
mas of the indicated stages compared with adjacent normal 
tissue. n = 100 normal lung specimens and 69, 12, and 13 
stage I, II, and III tumors respectively. Graph represents a 
Tukey plot, with the bar representing the median, the box 
representing the 25th and 75th percentiles, and the whiskers 
representing 1.5 times the interquartile distance. The P value 
was calculated using a 2-tailed unpaired t test. (B) Kaplan-
Meier survival curve for stage I tumors (n = 69) with normal 
(NL; >28th percentile) or low (LO; <27th percentile) USP44 
mRNA. The P value was calculated with the log-rank test.
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USP44 and cancer. We have found that animals lacking USP44 
are highly prone to spontaneous tumors, particularly of the lung. 
While other DUBs have been implicated as tumor suppressors 
based on mutations found in humans, USP44 is the first to our 
knowledge whose loss leads to spontaneous tumors in mice (42). 
While it is reasonable to conclude that the tumorigenesis in Usp44-
null mice is the result of aneuploidy, our results do not exclude the 
possibility that there are other mechanisms by which USP44 sup-
presses tumors. It is noteworthy, however, that many other models 
carrying mutant CIN gene alleles also have increased rates of lung 
adenoma formation (1). There is a strong association between lung 
cancer and aneuploidy (43). Recently, empiric evidence support-
ing the long-held belief that aneuploidy increases rates of loss of 
heterozygocity (LOH) was provided from studies using mice with 
reduced levels of the checkpoint protein BUB1 crossed with ani-
mals heterozygous for TP53 or APCmin (44). Further studies are 
needed to explore the role of USP44 in this process and the timing 
of its loss in the development of lung tumors in vivo.
Methods
Generation of Usp44-null mice and other mouse strains. Unlike other mamma-
lian genomes, the mouse Usp44 gene is annotated to consist of two exons 
of nearly equal size that are predicted to encode a protein of 505 amino 
acids lacking an active site cysteine. Using the human gene as a template, 
however, the genomic sequence of mouse chromosome 10 is predicted to 
encode a second Usp44 ORF consisting of 5 exons translated to produce a 
protein with 709 amino acids, including a full catalytic triad. This predict-
ed USP44 protein is 79% identical and 86% similar to human USP44. The 
expression of this “alternate,” more homologous transcript was verified by 
cloning the full-length mouse USP44 from cDNA generated from mouse 
kidney RNA, as well as by quantitative real-time PCR demonstration of 
the widespread presence of the “alternate” transcript in other mouse tis-
sues. We therefore based our design for the hypomorphic and null alleles 
of Usp44 on this alternate transcript, which we believe to encode the bona 
fide Usp44 gene. The construction of the Usp44 targeting vector was based 
upon the multipurpose targeting strategy described previously (45) and 
was carried out entirely using recombinational cloning techniques as 
described in ref. 46. Briefly, the Usp44 gene region was cloned into the 
targeting vector pDTA.4b via gap repair from a bacterial artificial chro-
mosome derived from AB2.2-ES cells (bMQ collection) obtained from 
Source Bioscience/Geneservice. The orphan loxP site was then introduced 
approximately 100 bp upstream of exon 1 by first inserting a loxP-Pgk-em7-
Neo-loxP cassette from plasmid PL452, followed by Cre-mediated excision 
of the neo ORF, leaving only a single loxP site. We then inserted an Frt-
Pgk-em7-Neo-Frt-loxP cassette from plasmid PL451 into the intronic region 
approximately 100 bp downstream of exon 1. The Neo ORF is in reverse 
orientation with respect to the Usp44 gene to allow the generation of a 
hypomorphic allele. The integrity of the resulting targeting construct was 
tested functionally by establishing the ability of the Cre recombinase to 
eliminate kanamycin resistance in bacteria (as successful excision removes 
the Pgk-em7-Neo construct in addition to exon 1), as well as through 
sequence confirmation of several regions of the construct. The construct 
was then linearized with ApaI and was introduced into murine ES cells by 
electroporation. G418-resistant colonies were screened for homologous 
recombination by Southern blotting using a probe amplified from a 750-
bp region that lies 3′ to the engineered region on chromosome 10. Clones 
with correct recombination were karyotyped prior to blastocyst injection. 
Following germline transmission, the floxed allele was generated by mat-
ing Usp44+/h animals with those carrying the Flpe recombinase in all tis-
sues (Jackson Laboratory, stock 007844). The null allele was generated 
USP44 and the centrosome. Here we describe a new function for 
USP44 in regulating centrosome separation and positioning. 
We identify and map a new interaction between USP44 and cen-
trin that is required to prevent chromosome lagging. The direct 
interaction between USP44 and centrin likely serves to localize 
USP44 to the centrosome, as this localization is disturbed when 
the centrin-binding motif is mutated. USP44 does not appear 
to prevent proteasomal degradation of centrin, as we found no 
changes in the level of centrin in Usp44-null MEFs, though redun-
dancy with other DUBs remains possible. The use of centrin as a 
centrosomal targeting mechanism may indicate that the substrate 
of USP44 is in close proximity to centrin, though further insights 
will require identification of the relevant substrate(s). The func-
tion of USP44 at the centrosome at least in part involves regu-
lating the events surrounding centrosome separation, as its loss 
leads to an increase in cells with incomplete centrosome separa-
tion. Recent work from the Cimini laboratory demonstrates that 
incomplete centrosome separation strongly predisposes cells to 
develop merotelic attachments, as the mitotic spindle microtu-
bules that emanate from abnormally positioned centrosomes can-
not efficiently probe the kinetochore landscape (28). This leads 
us to conclude that the lagging chromosomes seen in cells lack-
ing USP44 are the result of incomplete centrosome separation. In 
experiments using α-tubulin–GFP, we observed that that USP44 
loss caused cells to have difficulties in spindle geometry early in 
mitosis, though most cells eventually formed a reasonable meta-
phase plate. However, the cells with disturbed spindle geometry 
early in mitosis rarely were successful in distributing their chro-
mosomes properly, even though the spindle geometry appeared 
to have improved by anaphase. These data suggest that proper 
centrosome separation and early spindle assembly are essential 
for high-fidelity chromosome segregation.
The detailed events surrounding centrosome separation are 
not completely understood. In part, this process is triggered by 
the kinase NEK2A, which phosphorylates the proteins C-NAP1 
(CEP250) and rootletin (CROCC), which are thought to consti-
tute the inter-centrosomal linker (33, 34). The phosphorylation 
of these substrates leads to their eventual loss from the linker, 
allowing centrosome movement that is dependent on kinesin 
Eg5 (KIF11) (35). Several mitotic regulators, including UBCH10 
(UBE2C) (32), UBE2S (36), APC (37), and cyclin B1 (38), localize 
to the centrosome prior to or during mitosis, though the exact 
role for this localization is not clear. Knockdown of UBCH10 and/
or UBE2S leads to centrosome duplication errors in Drosophila S2 
cells (36). Most interestingly, the depletion of these Ub E2 enzymes 
also led to spindle defects, with abnormal geometry particularly 
seen in cells with low levels of UBE2S, where spindle pole posi-
tioning abnormalities were found. It is possible that a cycle of 
ubiquitination and deubiquitination of critical centrosome sub-
strates is also required in order to coordinate these processes. The 
spindle abnormalities seen in our study also have similarities to 
those seen in cells following depletion of proteins making up the 
Emi/NuMA/dynein/dynactin complex, also known as the END 
network (39, 40). Knockdown of any component of this network 
leads to similar centrosome positioning and spindle abnormali-
ties. Interestingly, an important role of this network includes the 
“anchoring” of APC at the spindle pole, a function that is thought 
to limit the activity of APC in early mitosis (41). It is tempting to 
speculate based on our data that restraining APC activity may be 
also important for the normal positioning of the centrosome.
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(Abcam); phospho–histone H3(Ser10) (Millipore, 06-570); cyclin B1 (SC-
245) and CDC20 (SC-8358; Santa Cruz Biotechnology Inc.); and human 
anti-centromere antibody (Antibodies Inc.). We screened all 7 published 
and commercially available USP44 antibodies and raised polyclonal anti-
sera using 6 distinct immunogens (3 peptide sequences and 3 protein 
fragments of 50–100 residues) in a total of 10 rabbits. All resulting anti-
sera were screened for the ability to detect a protein of the appropriate 
molecular weight (75–80 kDa) that increases in intensity and overlaps 
with HA-tagged USP44. No antisera satisfied these criteria. Commer-
cial USP44 antibodies tested included F-15, N-14, and S-14 (Santa Cruz 
Biotechnology); GTX87933 (GeneTex); SAB4503322 and HPA026543 
(Sigma-Aldrich); and 15521-1-AP (Proteintech). USP44 polyclonal anti-
sera were also provided by Kwang-Hyun Baek (50). Immunoblotting was 
performed using standard procedures. Immunoprecipitation was per-
formed as described previously (58). Codon-optimized murine USP44 
was cloned into pET3a with an N-terminal 6xHis tag (HisUSP44) and was 
introduced into the bacterial strain BL21. GST-tagged human centrin 2 
was previously described (59). Extracts of induced BL21 cultures were 
mixed and subjected to affinity purification with glutathione agarose 
(Pierce), followed by immunoblotting. The identity and migration of 
HisUSP44 was further verified by mass spectrometry.
USP44 activity assay. USP44WTHA, USP44C281AHA, and USP44W162AHA 
were immunoprecipitated from MEFs in the absence of any protease 
inhibitors; washed thoroughly; and resuspended in buffer containing 50 
mM HEPES, 150 mM NaCl, and 2 mM DTT. Equal amount of beads were 
transferred to separate tubes to which 500 ng di-Ub of the indicated link-
age type was added. After a 30-minute incubation at room temperature, 2× 
Laemmli SDS sample buffer was added to stop reactions, and the mixtures 
were immediately boiled for 5 minutes. Samples were resolved on a 15% 
polyacrylamide gel and immunoblotted for ubiquitin and HA to verify 
equal enzyme loading.
Immunofluorescence and fluorescence live-cell microscopy. Live-cell imaging 
experiments were performed as previously described in detail (18, 54). 
A lentiviral construct encoding YFP-tagged H2B (pTSIN-H2B-YFP) was 
used to visualize chromosomes by fluorescence microscopy. Indirect 
immunofluorescence was performed as described (58, 60). A laser scan-
ning microscope (LSM 510 v3.2SP2; Zeiss) with Axiovert 100M (Zeiss) 
with a c-Apochromat ×100 oil immersion objective was used to analyze 
immunostained cells and capture representative images. For quantifica-
tion of cyclin BCerulean and USP44Cherry levels at each mitotic stage, 10 or 
more cells were analyzed per each of 3 MEF lines. The mean fluorescence 
intensity was determined after background subtraction of images trans-
formed to 8-bit grayscale using ImageJ software (NIH). Imaging of cen-
trosomes was performed by transducing cells with γ-tubulin–CFP and 
H2B-RFP, followed by live-cell microscopy. Cells were marked in G2 (two 
centrosomes) and followed through mitosis. For the calculation of inter-
pole distances, only those images in which the two centrosomes were 
visible in the same focal plane were used, to avoid the need for z-stack 
images, as the imaging frequency required for this analysis often led 
to mitotic abortion. Imaging of the mitotic spindle in living cells was 
performed by transducing MEFs with α-tubulin–GFP and H2B-RFP, fol-
lowed by live-cell microscopy.
Gene expression profiling of lung tumors. All patients with a likely lung tumor 
who were undergoing wedge resection were approached for enrollment 
in the Mayo Lung Specimen Registry. Samples were acquired following 
receipt of informed consent and were completely de-identified for sub-
sequent analysis. Using the Mayo Clinic Lung Specimen Registry, lung 
specimens (n = 194) resected from non-neoplastic and tumor tissues from 
155 patients with lung adenocarcinoma (AD) between 1997 and 2007 were 
selected. Formalin-fixed, paraffin-embedded (FFPE) H&E sections from 
through mating with mice expressing Cre in the male germline (Prm-Cre; 
Jackson Laboratory, stock 003328). Analysis of the Usp44 gene reveals a 
possible alternative start site in exon 2 that would theoretically produce a 
190-residue protein lacking the conserved N-terminal zinc finger domain 
that is thought to be important for ubiquitin binding (47) and the cys-
teine that is essential for all non-JAMM/MPN class isopeptidases (48). 
Mad2l1+/– mice were a gift of Robert Benezra (Memorial Sloan-Kettering 
Cancer Center, New York, New York, USA) (49).
Evaluation of USP44 antibodies and confirmation of Usp44 deletion. In an 
attempt to detect USP44 by immunoblotting or immunofluorescence, 
we screened all 7 published and commercially available USP44 antibod-
ies, raised polyclonal antisera using 6 distinct immunogens (3 peptide 
sequences and 3 protein fragments of 50–100 residues) in a total of 10 
rabbits, and raised 6 monoclonal antibodies against distinct peptide epit-
opes. Commercial USP44 antibodies tested included F-15, N-14, and S-14 
(Santa Cruz Biotechnology Inc.), GTX87933 (GeneTex), SAB4503322 
and HPA026543 (Sigma-Aldrich), and 15521-1-AP (Proteintech). USP44 
polyclonal antisera were also provided by Kwang-Hyun Baek (CHA Stem 
Cell Institute, College of Medicine, CHA University, CHA General Hospi-
tal, Seoul, Republic of Korea) (50). All commercial and custom-produced 
antisera were tested in human and mouse cells and screened by the ability 
to (a) recognize a band at the expected size (75–80 kDa) and (b) detect a 
band of increased intensity of the appropriate size in cells overexpressing 
mouse or human USP44-HA and by (c) failure to detect a 75- to 80-kDa 
band in Usp44-null MEFs. No antibody satisfied these criteria. The deletion 
of exon 1 was therefore verified by Southern blotting, direct sequencing, 
and by RT-PCR on RNA from MEFs (Supplemental Figure 1, A–E).
Cell culture, reagents, and cloning. Cells used in this study include MEFs 
that were generated from day 13.5 embryos (51). All experiments were 
performed on primary MEFs between passages 2 and 5, with the excep-
tion of CDC20 immunoprecipitation (Supplemental Figure 3), which was 
performed using mitotic MEFs immortalized with SV40 large T antigen 
(52). All MEFs were cultured as described previously (32). For all experi-
ments, at least 3 independent MEF lines were used. Chromosome counts 
on MEFs were performed as previously described (44, 53). Spectral karyo-
typic analysis and FISH were performed by the Mayo Clinic Cytogenetics 
Core Facility, using the protocol, reagents, instrumentation, and software 
from Applied Spectral Imaging. Cell synchronization was performed as 
described previously (54). Generation, use, and quantitation of cyclin B1–
venus were performed as described (55). The C-terminally tagged USP-
44WTHA and USP44Cherry constructs were previously described (19). The 
USP44 mutant constructs were generated using the GeneArt mutagen-
esis kit (Invitrogen). All USP44, α-tubulin, and γ-tubulin constructs were 
cloned into the lentiviral vector pTSiN, and virus production was per-
formed as described previously (56). MEFs were transduced by culturing 
with a 1:1 mixture of fresh medium and virus supernatant with Polybrene 
(4 μg/mg final concentration) for 24–72 hours. All experiments were per-
formed on polyclonal pools of transduced cells. For the experiments with 
proTAME, MEFs were imaged for 2 hours to determine the pretreatment 
(“before”) mitotic duration and chromosome mis-segregation rate. Fol-
lowing this period of observation, the APC inhibitor proTAME (a gift 
from Randy King, Harvard Medical School, Boston, Massachusetts, USA) 
was added (6 μM), followed by a 2-hour period to allow the drug to take 
effect. Cells were then monitored again for mitotic timing and chromo-
some mis-segregation (“after”).
SDS-PAGE, antibodies, immunoblotting, and immunoprecipitation. Anti-
bodies used in this study included anti-HA (clone 3F10; Roche Applied 
Science); centrin 2/3 (20H5; ref. 57); centrin 2 (Proteintech); γ-tubulin 
(Abcam); BubR1 (catalog 612503), Cdc27 (catalog 610454), and Mad2 
(catalog 610678, BD Biosciences); BubR1 (51), Mad2, and securin 
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